AVADEL PHARMACEUTICALS PLC
AVADEL PHARMACEUTICALS PLC (AVDL): 2 pipeline candidates · ~4 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.3 months
D/E 1.03 · 4% dilution
Lead: Phase 3
2 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for AVADEL PHARMACEUTICALS PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.1B
Cash
$79.8M
Quarterly Burn
$79.6M
Runway
4.3 mo
Revenue
$77.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in AVADEL PHARMACEUTICALS PLC's pipeline?
AVADEL PHARMACEUTICALS PLC (AVDL) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AVADEL PHARMACEUTICALS PLC's lead drug candidate?
AVADEL PHARMACEUTICALS PLC's most advanced tracked candidate is FT218 (Phase 3) for Idiopathic Hypersomnia.
What is AVADEL PHARMACEUTICALS PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AVADEL PHARMACEUTICALS PLC has approximately 4.3 months of cash runway.
What is AVADEL PHARMACEUTICALS PLC's market capitalization?
AVADEL PHARMACEUTICALS PLC's market capitalization is approximately $2.1B.
Who is the CEO of AVADEL PHARMACEUTICALS PLC?
Chief Executive Officer is the chief executive officer of AVADEL PHARMACEUTICALS PLC (AVDL).
Get the full picture on AVADEL PHARMACEUTICALS PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.